A Dependency Investigation (#02) – May, 2026
About This Series
The Magician’s Hands is a series of dependency investigations. Each report examines a single case in which a structural dependency, between a state and an infrastructure owner, a farmer and a seed company, a continent and an energy supplier, was created, normalised, leveraged, and converted into power. The cases span domains and decades. The grammar beneath them does not change.
The series takes its name from a simple observation: the most consequential things happening in the world are rarely the things that take centre stage. While we watch the visible hands, something else is being built in the structural layer underneath. These reports are an attempt to make that layer legible.
The founding article, “”, sets out the full grammar. Each investigation that follows applies it to a specific case.
Scene-setter
The visible story of Monsanto is one most people in agriculture know by instinct even if they cannot place the details. A chemical company reinvents itself as a life sciences company, develops herbicide-tolerant crops, sells them alongside its own herbicide, patents the genetics, and grows until its name becomes synonymous with the industrialisation of farming. The debates it generated were loud: environmentalists argued about genetic modification, farmers complained about corporate power, governments commissioned reviews. The visible hands moved visibly.
What received less attention was the structural layer being assembled underneath those debates. Monsanto was not primarily a seed company that made farmers dependent on its seeds. It was a dependency architecture company that used seeds as its delivery mechanism. The patents were not the point. The patents were the instrument through which a biological process as old as agriculture itself, the capacity to save seed from one harvest and plant it in the next, was converted into a contractual obligation and then into an annual fee. The dependency was not between a farmer and a corporation. It was between a nation’s food supply and a privately owned genetic library, with a subscription model embedded into the soil.
This investigation traces how that architecture was built, how it was made to feel like progress, how it was used once it was load-bearing, and what was ultimately converted in the process. It will show that what looks like a corporate success story is, in its structural grammar, a case of dependency creation at civilisational scale: the enclosure of a biological commons, executed one licensing agreement at a time.
Move 1: Creating the Dependency
The entry point is creation, and the utility was genuine. That is what makes this case structurally interesting and what made it so durable. Roundup Ready soybeans, first commercially planted in 1996, were not a fraud. They worked. Farmers who adopted them could spray glyphosate herbicide directly over their crops and kill the weeds without killing the plants. Labour costs fell. Yields were more consistent. The farming calculus, evaluated at the individual farm level in the mid-1990s, pointed clearly toward adoption. The hook was real.
What individual farmers could not see at the moment of adoption was that Monsanto had redesigned the relationship between seed and harvest at the contractual level before it sold a single bag. The technology use agreements that farmers signed prohibited them from saving seed for replanting. This was not an unusual clause buried in fine print; it was the commercial centre of the entire system. Monsanto’s business model did not require farmers to be locked in by force. It required that the moment of lock-in be mistaken for a straightforward purchase. A farmer who bought Roundup Ready seed was not buying a product. They were entering a subscription relationship with an annual renewal clause, backed by Monsanto’s intellectual property rights and, where necessary, its litigation programme.
The seed-herbicide pairing deepened the architecture. Roundup Ready crops were optimised for use with Monsanto’s own glyphosate herbicide, Roundup. Farmers who adopted the seed system found it most efficient to adopt the herbicide system alongside it. This was not compulsion; it was integration. But integration creates its own momentum. Within a few seasons, Roundup became the default herbicide of choice across the adopting population not because of aggressive salesmanship but because the crop system was designed around it. The dependency on seed and the dependency on chemical were structurally linked, amplifying each other.
The moment the dependency became costly to reverse was earlier than most farmers recognised. It arrived not when Monsanto filed its first lawsuit, but when Roundup Ready traits reached sufficient market penetration that non-Monsanto seed varieties became difficult to source, when crop rotations built around glyphosate tolerance had reorganised field management practices, and when the equipment, the labour patterns, and the agronomic knowledge embedded in a farm operation had all oriented themselves around the system. By that point, exit was not a decision about a seed purchase. It was a decision to reconstruct the operational logic of a farming enterprise from the ground up.
Move 2: Normalising the Dependency
Narrative normalisation arrived dressed as science. Monsanto invested heavily in positioning genetic modification as the next chapter of the Green Revolution: a technology-led solution to hunger, productivity, and the challenge of feeding a growing planet. The institutions that carried this narrative were not fringe actors. The US Department of Agriculture, university extension programmes substantially funded by agribusiness, and mainstream agricultural media all became carriers of a story in which the adoption of Monsanto’s technology represented rational modernisation. Farmers who expressed scepticism were positioned as resistant to progress. Activists who raised structural concerns were dismissed as technophobic or ideologically motivated. The counter-narrative failed to land not because it was wrong but because it was framed as an emotional reaction to science rather than a structural critique of a dependency being built.
The specific question that the narrative made effectively unaskable was this: what does it mean to convert the reproductive capacity of a seed into a licensed transaction? The Green Revolution framing kept the conversation on yield and productivity. It kept it away from the question of who would own the genetic foundation of the food system once the transition was complete. That question was not suppressed by conspiracy; it was simply outside the frame that the dominant story made available.
Operational normalisation ran on a separate track and was in many respects more powerful. By 2010, Monsanto’s Roundup Ready traits were present in 93% of US soybeans, a figure confirmed by the National Agricultural Statistics Service, and in approximately 82% of US corn. At that scale, the dependency stopped being a relationship between a company and its customers and started being infrastructure: the genetic substrate of American agriculture. Farmers sourcing seed in the open market were not choosing between Monsanto and an alternative. They were operating in a market that Monsanto’s traits had redefined. The switching cost was no longer about preference; it was about the availability of non-trait seed varieties, the herbicide resistance patterns already established in their fields, and the fact that their neighbours, their suppliers, and their grain buyers had all oriented around the same system.
The dependency had become, in the most precise sense, simply how agriculture worked.
Move 3: Leveraging the Dependency
Direct leverage was exercised through the litigation programme, and Monsanto made no particular secret of it. The company employed a team of investigators to identify farmers suspected of saving and replanting patented seed, and between 1997 and 2010 it filed 144 lawsuits against farmers in at least 27 states for alleged infringement of its transgenic seed patents, settling a further 700 cases out of court. The cases that reached public attention served a function beyond their immediate legal outcomes. They signalled to every farmer in the adopting regions that the licensing terms were not advisory. The dependent party understood that the dependency was monitored and enforced.
The most closely watched case was that of Percy Schmeiser, a Canadian canola farmer whose fields were found to contain Roundup Ready traits at concentrations between 95% and 98% of his 1,000-acre canola crop. The Supreme Court of Canada ruled in May 2004 that Schmeiser had infringed Monsanto’s patent by knowingly saving and replanting the resistant seed, though the court also found, unanimously, that he owed no damages, as he had not commercially benefited from the trait. The outcome gave something to both sides. What it established beyond dispute was that the presence of patented genetics in a farmer’s crop, regardless of how they arrived, could constitute infringement under patent law. That precedent had consequences far beyond Saskatchewan.
Structural leverage operated through the seed market itself. As Monsanto acquired independent seed companies throughout the 1990s and 2000s, it was not simply expanding its portfolio. It was reducing the number of actors capable of providing competitive alternatives. The consolidation of the seed industry meant that farmers negotiating over price, over trait availability, over contract terms, were doing so with a market that had been progressively narrowed. The decision visible to any individual farmer was which seed to buy. What was not equally visible was that the architecture of the market making that decision had been shaped by two decades of acquisition activity.
Option-space leverage operated at the policy level in ways that rarely broke the surface. Regulatory frameworks for genetically modified organisms in the United States evolved in an environment in which Monsanto and its industry peers were significant participants in the standard-setting conversations. The result was not regulatory capture in its crudest form. It was something structurally subtler: an approval framework whose design assumptions aligned with the commercial model of the companies seeking approval. Labelling requirements that would have made the dependency visible to consumers were consistently resisted. Coexistence standards that would have protected non-adopting farmers from trait contamination were never established at a level that made non-adoption economically viable for most. The option space available to farmers, consumers, and regulators had been quietly narrowed before any specific policy decision was made.
Move 4: Obscuring the Mechanism
The temporal displacement in this case is substantial and structural. The decisions that created the dependency, the 1980 Diamond v. Chakrabarty Supreme Court ruling that established living organisms as patentable subject matter, the subsequent extension of that framework to plant genetics, and the regulatory architecture established for GMO approval in the early 1990s, were made by actors who would not be the ones to face the consequences of their downstream combination. By the time the dependency was load-bearing, the political figures, the regulators, the institutional decision-makers who had assembled its enabling architecture had long since moved on. The farmers and food systems that inherited the consequences had not been present at the decisions that created them.
Diamond v. Chakrabarty did not itself patent a seed. What it did was open the conceptual and legal door through which the entire subsequent architecture of biological IP walked. The 5-4 ruling held that a human-made microorganism capable of breaking down crude oil was patentable subject matter. The logic it established, that something engineered by human ingenuity and not occurring in nature could be owned, was extended in subsequent decades to plant cells, gene sequences, and the specific genetic modifications embedded in crop varieties. The connection between that 1980 ruling and a farmer’s annual seed bill in 2005 runs through twenty-five years of legal, regulatory, and commercial decisions. That is precisely the kind of line that democratic accountability cannot trace.
This temporal gap was structurally protective. Democratic accountability requires a legible line between a decision and its consequence. When that line runs across decades, across multiple institutions, across the accumulated effect of individually defensible choices, the line becomes impossible to draw in a way that mobilises political response. Monsanto did not need to obscure the mechanism in the sense of hiding documents. The mechanism obscured itself through distributed decision-making, jurisdictional complexity, and the simple passage of time.
Narrative capture operated through a related but distinct mechanism. The story available to most observers framed the dispute as being between farmers and corporations, or between environmental activists and the agricultural industry. These framings were accurate as far as they went. But they kept attention on the actors rather than on the architecture. The question of whether biological reproduction should be patentable at all, and what the consequence of answering yes would be for the long-term structure of food systems, was a question that required engaging with IP law, genetics, agricultural economics, and geopolitical food security simultaneously. The institutional architecture to assemble and interpret that composite picture did not exist in any coherent form. The relevant information was available in scattered pieces across legal filings, academic literature, advocacy reports, and regulatory dockets. The capacity to read it whole, to see the grammar rather than the individual moves, was not.
Move 5: Converting the Value
The financial conversion is the one most commonly reported. Monsanto’s seed and trait revenues grew from a negligible base in the mid-1990s to billions of dollars annually by the time of its acquisition by Bayer AG in 2018 for approximately $63 billion. The technology fee embedded in every bag of licensed seed represented a recurring extraction from the farming economy that had no precedent in the history of agriculture. Farmers had always paid for seed. They had not always paid a royalty to a patent holder for the genetic capacity of the seed to reproduce.
But the financial conversion is not the most consequential one.
The normative conversion is. Monsanto did not merely make money from seeds. It established, through the combination of legal precedent, commercial scale, and regulatory entrenchment, that biological processes are ownable. The Diamond v. Chakrabarty framework and the intellectual property architecture that developed around it created a normative landscape in which the genetic information embedded in a living organism could be treated as private property. That normative shift did not stay within the boundaries of one company’s commercial programme. It became the framework within which the entire global seed industry subsequently operated. By 2018 to 2020, the top four seed companies, Bayer/Monsanto, Corteva, Syngenta, and BASF, controlled 84% of the US corn seed market and 78% of the US soybean seed market, all operating within a legal and normative architecture that Monsanto’s early moves did more than any other single actor to establish.
The strategic conversion is geopolitical. A nation’s food security is a function of its seed sovereignty: its capacity to produce food independently of decisions made by foreign actors. The concentration of genetic ownership in a small number of predominantly Western corporate actors represents a structural exposure that most food-importing nations have not adequately mapped and that even food-exporting nations like the United States have obscured through the conflation of corporate agricultural dominance with national agricultural strength. India represents the case where this conversion became partially visible. By the mid-2000s, Bt cotton varieties incorporating Monsanto’s technology had spread across the great majority of India’s cotton acreage, transforming the country into the world’s largest cotton producer. The royalty dispute that followed, leading the Indian government to slash technology fees by 74% in March 2016 and the subsequent legal battles over whether India’s Patents Act excluded Monsanto’s gene sequences from patentability under Section 3(j), revealed what seed dependency looks like when a government attempts resistance. The leverage available to Monsanto, and subsequently to Bayer, was not military or diplomatic. It was the withdrawal of new technology from a market that had reorganised itself around traits it no longer had the independent capacity to produce.
The ecological conversion is the one with the longest tail. Glyphosate-resistant weeds, the predictable biological response to monoculture herbicide use at scale, now colonise tens of millions of acres of American farmland. The farming system that the dependency created is generating the conditions of its own escalation: stronger herbicides, additional trait stacking, intensifying chemical dependency layered onto the original genetic dependency. The farmers who adopted the system rationally in 1996 are not the ones who will bear the full cost of the soil ecology their adoption helped create. That cost has been deferred and distributed across the food system, across future growing seasons, and across the communities that live downstream of the fields where glyphosate has accumulated. Bayer has faced the leading edge of that deferred liability directly: it reached a settlement of between $10.1 billion and $10.9 billion in June 2020 to resolve the majority of US Roundup litigation at that time, while litigation has continued since, with a further proposed class settlement of $7.25 billion announced in February 2026 and receiving preliminary court approval in March 2026 to address remaining and future claims.
Move 6: Eliminating Alternatives
This move applies directly and is not absorbed by the preceding analysis. The elimination of alternatives was not incidental to Monsanto’s commercial strategy; it was structural to it.
Monsanto systematically acquired independent seed companies across two decades. The acquisition programme was not primarily about product lines. It was about the removal of competitive genetic libraries from independent ownership. Each acquisition narrowed the number of actors capable of offering non-patented or differently patented alternatives. By the time the consolidation wave was substantially complete, the heritage and open-pollinated seed sector had contracted to a fraction of its former commercial presence. Farmers seeking non-GMO varieties in commodity crop categories found themselves operating in a market where availability, agronomic support, and supply chain infrastructure had all degraded.
The legal architecture reinforced the market architecture. Farmers who saved Roundup Ready seed and replanted it were in breach of contract. The Schmeiser precedent, and the parallel Bowman v. Monsanto ruling by the US Supreme Court in 2013, established that patent rights extended to every generation of a self-replicating organism, not merely the original sold seed. The practical effect was that the spread of the genetic technology itself, a spread partly driven by natural biological processes that no farmer could fully control, simultaneously expanded Monsanto’s legal reach and reduced the viable acreage available to non-adopters. The boundary between adoption and contamination was not always clear, but the legal consequence on both sides of that boundary ran in the same direction.
The result was a seed market in which the elimination of alternatives was written into the biology of the fields themselves.
Analytical Notes
The India case represents the most significant point of partial resistance in this investigation, and what it reveals about the grammar is instructive. Resistance succeeded at the leverage move, not at the creation or normalisation moves. By the time the Indian government moved to cap Monsanto’s technology fees in 2016, Bt cotton was already present in the overwhelming majority of Indian cotton agriculture and the operational dependency was fully established. What India’s regulatory structure provided was not the capacity to exit the dependency but the capacity to contest its price. The Patents Act provision under Section 3(j), which excludes plants and essentially biological processes from patentability, gave the government and Indian seed companies a legal lever that equivalent provisions in US or European law did not offer in the same form. The Delhi High Court invoked it directly in 2018 to invalidate Monsanto’s Bt cotton patent in India, a ruling later overturned on procedural grounds by the Supreme Court of India in 2019, which remanded the case for full trial, leaving the underlying Section 3(j) question unresolved. The resistance was partial precisely because it arrived after normalisation was complete. It could affect the terms of the dependency but not the dependency itself. That is the structural lesson: the grammar’s most durable phase is normalisation, because resistance after that point is always more expensive than resistance before it.
Closing
What this case reveals about the grammar is something the founding article names but does not fully develop: the dependency does not need to be concealed. It needs only to be mistaken for something else. Monsanto’s seed patents were not hidden. The licensing agreements were signed in full daylight. The litigation programme was a matter of public record. What was not visible was not the mechanism but its meaning: the fact that a sequence of individually defensible commercial decisions was assembling a structural architecture whose full implications would only become legible decades later, when the switching costs had been built into the soil.
The Monsanto case also illustrates the civilisational reach that dependency grammar can achieve when it operates at the biological layer. Software dependencies trap workflows. Infrastructure dependencies trap supply chains. Genetic dependencies trap the reproductive capacity of living systems. The grammar is the same. The consequence at scale is categorically different. A nation that cannot source food independently has lost something that no diplomatic or military capability can quickly recover.
The question the reader should carry forward is not whether this could happen again. It is already happening, in the concentrated ownership of the gene-editing platforms that will define the next generation of crop development, in the intellectual property frameworks being negotiated around CRISPR and related technologies, in the regulatory environments being shaped now by the same concentrated actors who inherited the architecture Monsanto built. The hands are visible. The question is whether we are watching the right ones.
Comments are closed